Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You 3 Undervalued Names Too Cheap to IgnoreAuthored by Nathan Reiff. Article Published: 3/7/2026. 
Quick Look - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies out there may make 2026 seem like an odd time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with valuation metrics that are historically low or competitive versus peers and the broader market. They also offer added benefits, such as compelling dividends or promising product developments. While true value opportunities can be harder to find when many names have regained investor attention—or when apparent bargains hide operational red flags—well-established, stable companies can still present worthwhile value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Famed historian Yuval Noah Harari recently issued a warning that should send a shiver down the spine of every American. He predicts the emergence of a massive new useless class. These aren't just people who are temporarily unemployed. These are people who have become economically irrelevant. As Luke Lango and I just exposed in our recent interview, we have reached the singularity. For the first time in 250 years, intelligence has been decoupled from labor. During America's first 1776 moment, the steam engine replaced muscle. In this new 1776 moment, AI is replacing the human mind.
This is why you see the Magnificent 7 tech giants adding trillions in value while the real economy feels like it's in a death spiral. The divide is widening. On one side: the useless class who cling to old-world skills. On the other: the new aristocracy who own the assets of the technological republic. Luke and I have identified the three specific money moves our research indicates you must make to ensure you stay on the winning side of this divide. See the three moves to stay on the winning side of AI Although shares have climbed more than 28% over the past year, lifting Merck & Co. Inc.'s (NYSE: MRK) market capitalization to nearly $300 billion, the biopharma giant still trades at a price-to-earnings (P/E) ratio of about 16.45—well below the medical industry average near 27. Analysts expect continued growth: earnings are projected to rise nearly 10% next year, and the stock shows roughly 5% upside in the near term. Helping drive Merck's momentum is its pembrolizumab cancer drug, Keytruda, which was approved for subcutaneous injection by the European Commission in late 2025 and generated about $8.4 billion in sales in Q4 2025, up almost 7% year-over-year (YOY). Keytruda also shows promise in ovarian cancer, potentially expanding its patient base. These developments should help Merck build revenue as Keytruda approaches patent expiration in 2028. Merck's portfolio is broadening as well, including recent phase 3 trial results for clesrovimab-cfor (branded as Enflonsia), a treatment for RSV in young children. At the same time, the company is reorganizing its human health business into two units to better position itself to grow non–cancer-drug sales ahead of Keytruda's patent loss. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Campbell's (NASDAQ: CPB) shares have dropped about 37% over the last year as the food-and-beverage staple faced pressure from tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company posted modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share (EPS) fell roughly 13%. Margin improvement has been limited so far despite cost-saving initiatives. The near term is likely to remain challenging given weak full-year guidance. That said, improvements to the supply chain and strong brand loyalty—particularly for premium product lines—should help protect sales. Evolving tariff dynamics may also ease some external pressure. On top of that, Campbell's remains a notable dividend play, offering a yield of 5.9%, though its payout ratio is fairly high at over 80%. Campbell's P/E of about 13.5 is the lowest it's been in roughly four years. Those factors may attract income-focused investors despite Wall Street's cautious outlook. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice-distribution leader US Foods (NYSE: USFD) has moved almost opposite to Campbell's—shares are up roughly 33% over the past year. Still, its P/E ratio, at about 31.6, is reasonable relative to its growth prospects. Fundamentally, US Foods is making strides: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year-over-year. Better inventory management and savings on cost of goods sold are helping the firm gain traction. With a $4 billion capital-deployment plan in place, US Foods is positioned to sustain revenue momentum and continue expanding adjusted EBITDA. Analysts rate USFD a Moderate Buy (11 Buys, 2 Holds), implying roughly 15% upside potential.
| 
